Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is prevalent in patients with coronary artery disease (CAD).
• Current guidelines recommend 12 months of dual antiplatelet and anticoagulation therapy post-percutaneous coronary intervention (PCI) in AF patients, followed by anticoagulation alone.
• There is limited evidence on the efficacy of long-term anticoagulation alone in preventing stent thrombosis, especially very late stent thrombosis (>1 year).

Purpose of the Study:

• To review the evidence for using anticoagulation therapy alone beyond 1 year post-PCI in AF patients.
• To evaluate the balance between the risk of stent thrombosis and the risk of bleeding with long-term anticoagulation alone versus dual therapy.

Main Methods:

• Systematic review of existing literature and clinical guidelines.
• Analysis of studies investigating stent thrombosis and bleeding risks associated with antiplatelet and anticoagulation therapies.

Main Results:

• Evidence supporting anticoagulation alone to prevent stent thrombosis, particularly very late stent thrombosis, is sparse.
• Dual therapy significantly increases bleeding risk, which is a major clinical concern.

Conclusions:

• Further research is needed to establish the optimal long-term antithrombotic strategy for AF patients post-PCI.
• Balancing the risk of stent thrombosis and bleeding remains a critical challenge in managing these high-risk patients.